阿尔茨海默病患者脑脊液中的高尔金A4与颗粒空泡变性
研究通过免疫小鼠制备单克隆抗体筛选脑脊液标志物,鉴定出高尔金A4,并在新队列中定量检测其脑脊液浓度,同时进行尸检脑组织免疫组化。结果显示阿尔茨海默病患者脑脊液高尔金A4浓度显著高于对照,且尸检脑组织中高尔金A4在颗粒空泡变性小体中显著积聚。结论支持高尔金A4可作为阿尔茨海默病的诊断标志物,需前瞻性多中心诊断研究验证。
要点
- 阿尔茨海默病患者脑脊液高尔金A4浓度显著高于对照,曲线下面积0.80。
- 尸检脑组织免疫组化显示高尔金A4在颗粒空泡变性小体中显著积聚。
- 研究提供III级证据表明脑脊液高尔金A4升高可识别阿尔茨海默病患者。
核心结论
- 结果支持高尔金A4可能作为阿尔茨海默病的诊断标志物。
- 需前瞻性多中心诊断研究验证高尔金A4作为阿尔茨海默病诊断标志物。
- 尚需确定高尔金A4与颗粒空泡变性小体的关联是附带现象还是直接作用,从而决定其能否作为治疗靶点。
研究设计与样本
- 用人类脑脊液免疫小鼠并融合杂交瘤制备单克隆抗体,筛选能区分阿尔茨海默病患者与对照脑脊液的抗体。
- 通过色谱法分离最佳区分抗体的抗原,并用质谱法鉴定抗原。
- 在新队列的阿尔茨海默病患者与对照中定量检测该抗原的脑脊液浓度。
- 对阿尔茨海默病患者与对照的尸检脑组织进行免疫组化。
主要发现
- 生成超过200个杂交瘤,筛选出1个能区分阿尔茨海默病患者与对照脑脊液的抗体。
- 鉴定出该抗体检测的抗原为高尔金A4。
- 阿尔茨海默病患者脑脊液高尔金A4浓度显著高于对照(145[四分位距125-155] vs 115[99-128] pg/mL,p < 0.001)。
- 高尔金A4的判别能力曲线下面积为0.80(95%置信区间0.67-0.94)。
- 阿尔茨海默病患者尸检脑切片免疫组化显示高尔金A4在颗粒空泡变性小体中显著积聚。
关键数值与推荐
- 本研究提供III级证据表明脑脊液高尔金A4水平升高可识别阿尔茨海默病患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To isolate and identify a new, as yet unknown molecule in CSF that could serve as marker for Alzheimer disease. METHODS: We immunized mice with human CSF and fused hybridomas for monoclonal antibodies and screened these antibodies for their capacity to discriminate CSF of patients with Alzheimer disease from CSF of controls. We then chromatographically isolated the antigen to the best discriminating antibody and identified the antigen using mass spectrometric methods. Thereafter, we quantified the CSF concentration of the antigen in a new cohort of patients with Alzheimer disease and controls and performed immunohistochemistry of postmortem brain tissue derived from patients with Alzheimer disease and controls. RESULTS: We generated >200 hybridomas and selected 1 antibody that discriminated CSF from patients with Alzheimer disease from that of controls. We identified golgin A4 as the antigen detected by this antibody. Golgin A4 concentration was significantly higher in CSF from patients with Alzheimer disease than in CSF of controls (145 [interquartile range 125-155] vs 115 [ 99-128] pg/mL, p < 0.001) and demonstrated a substantial discriminative power (area under the receiver operating characteristic curve 0.80, 95% confidence interval 0.67-0.94). Immunohistochemistry of postmortem brain sections from patients with Alzheimer disease revealed a significant accumulation of golgin A4 in granulovacuolar degeneration bodies (GVBs). CONCLUSIONS: These results support the notion that golgin A4 could serve as a diagnostic marker in Alzheimer disease. For validation of this notion, prospective multicenter diagnostic studies will evaluate golgin A4 as diagnostic marker for Alzheimer disease. Furthermore, it has to be determined whether the association of golgin A4 with GVBs is an epiphenomenon or whether golgin A4 plays a more direct role in Alzheimer disease, allowing it to serve as a target in therapeutic treatment strategies. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that elevated CSF golgin A4 levels identify patients with Alzheimer disease.
引用
- Kork F, Jankowski J, Goswami A, et al. Golgin A4 in CSF and granulovacuolar degenerations of patients with Alzheimer disease. Neurology. 2018. PMID: 30305446. doi:10.1212/WNL.0000000000006457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。